<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02235298</url>
  </required_header>
  <id_info>
    <org_study_id>20140671</org_study_id>
    <nct_id>NCT02235298</nct_id>
  </id_info>
  <brief_title>Effects of Dapagliflozin on Epicardial Fat in Subjects With Type 2 Diabetes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dapagliflozin is a new and emerging anti-diabetes medication. Dapagliflozin is a selective
      sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type
      2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a
      consistent associated finding. Because dapagliflozin increases urinary glucose excretion,
      weight loss could result from reduced body fat secondary to caloric loss or from fluid loss
      secondary to osmotic diuresis or from a combination of both factors. Nevertheless, whether
      Dapaglifozin may cause a reduction in visceral fat is unknown.

      Hence, in this study the investigators would like to test the hypothesis that Dapaglifozin
      causes a rapid and significant reduction of the epicardial fat, the visceral fat of the
      heart, in type 2 diabetic patients.

      This hypothesis would be tested in a prospective interventional study in 100 overweight or
      obese type 2 diabetes subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epicardial fat Thickness</measure>
    <time_frame>6 months</time_frame>
    <description>Epicardial fat thickness will be measured with echocardiography according to the method described and validated by Iacobellis et al</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapaglifozin will be administered the dose of 5 mg once daily. Metformin regimen will be continued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapaglifozin causes a rapid and significant reduction of epicardial fat in type 2 diabetic patients</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Type 2 diabetes, as defined by ADA criteria

               -  HbA1c ≤ 8% measured at least 1 week prior to the study

               -  BMI ≥27 kg/m2

               -  Pre-treatment with Metformin as monotherapy

               -  Age &gt; 18 and &lt; 70 years old

        Exclusion Criteria:

          -  • Known contra-indications to Farxiga, in accordance with risks and safety information
             included in the latest updated Prescribing Information

               -  Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria

               -  Insulin dependent or treated type 2 diabetes

               -  Current use of other SGLT2 inhibitors, GLP- 1 analogs or DPP4 inhibitors

               -  Glomerular Filtration Rate (GFR) &lt; 60 mL/min/1.73 m2

               -  Patients with poor glycemic control will be excluded to maximize long-term
                  patient retention without need

               -  History of diabetes ketoacidosis

               -  Clinical signs or symptoms of New York Heart Association (NYHA) class III-IV
                  heart failure

               -  Clinical or laboratory evidences of chronic active liver diseases

               -  Acute or chronic infective diseases

               -  Cancer or chemotherapy

               -  Current use of systemic corticosteroids or in the 3 months prior this study

               -  Known or suspected allergy to Dapaglifozin, excipients, or related products

               -  Pregnant, breast-feeding or the intention of becoming pregnant

               -  Females of childbearing potential who are not using adequate contraceptive
                  methods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gianluca Iacobellis, MD PhD</last_name>
    <email>giacobellis@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Young</last_name>
    <email>Myoung@med.miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Iacobellis, MD PhD</last_name>
      <email>giacobellis@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Gianluca Iacobellis, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Iacobellis, MD PhD</last_name>
      <email>giacobellis@med.miami.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2014</study_first_submitted>
  <study_first_submitted_qc>September 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2014</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Gianluca Iacobellis</investigator_full_name>
    <investigator_title>Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>epicardial fat</keyword>
  <keyword>diabetes</keyword>
  <keyword>dapagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

